Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520403 | 1.00 | CSNK2A1 (0.50) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| Hydrochloric Acid SCHEMBL30051933 | 0.98 | CSNK2A1 (0.52) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL17186197 | 0.83 | TAAR1 (0.67) | PNMTTAAR1 | |
| SCHEMBL1363230 | 0.82 | CSNK2A1 (0.46) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL1535743 | 0.79 | IDO1 (0.38) | PNMTTAAR1CYP3A4IDO1 | |
| SCHEMBL507688 | 0.79 | CYP4F2 (0.40) | PNMTTAAR1CYP3A4IDO1 | |
| SCHEMBL29349576 | 0.78 | PNMT (0.67) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL112200 | 0.78 | PNMT (0.67) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B | |
| SCHEMBL28958238 | 0.78 | HRH3 (0.43) | CSNK2A1PNMTTAAR1LOXL2LOX | |
| SCHEMBL29875339 | 0.78 | HRH3 (0.43) | CSNK2A1PNMTTAAR1LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2026-01-22 | — | — | US | disclosed |
| EP-4559905-A2 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-04-06 | — | — | US | disclosed |
| CN-115776891-A | STAT degradants and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-109311819-B | Isoquinolin-3-yl carboxamides, their preparation and their use | 萨穆梅德有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220332698-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281097-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | CSNK2A1 144/4885PNMT 3422/4885TAAR1 4856/4885 |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | CSNK2A1 26/4885PNMT 3571/4885TAAR1 3513/4885 |
| US-11548872-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | WNT1, WNT3, WNT3A | CSNK2A1 144/4885PNMT 3422/4885TAAR1 4856/4885 |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | CSNK2A1 26/4885PNMT 3571/4885TAAR1 3513/4885 |
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CSNK2A1 59/4885PNMT 4801/4885TAAR1 4779/4885 |
| US-20220332698-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | CSNK2A1 144/4885PNMT 3422/4885TAAR1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.